India’s NPPA has approved capping trade margins on non-scheduled cancer drugs at 30% of MRP, targeting markups that averaged about 170% and reached 700% in some cases. What it means for patients and how will the cap work?
​India’s NPPA has approved capping trade margins on non-scheduled cancer drugs at 30% of MRP, targeting markups that averaged about 170% and reached 700% in some cases. What it means for patients and how will the cap work? by Soban News (international And National News)
